An interesting preprint paper re liothyronine.
(Apologies for SHOUTING - using capitals - but I usually try to copy exactly.)
Thyroid. 2023 Sep 19.
doi: 10.1089/thy.2023.0135. Online ahead of print.
PRELIMINARY RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL EVALUATING THE CARDIO-METABOLIC EFFECTS OF LEVOTHYROXINE AND LIOTHYRONINE COMPARED TO LEVOTHYROXINE WITH PLACEBO IN ATHYREOTIC LOW RISK THYROID CANCER PATIENTS
Bernadette Biondi MD 1 2 , Martina Pucci 3 , Gilda Pontieri 4 , Pietro Formisano 5 , Roberta Esposito 6
PMID: 37725587 DOI: 10.1089/thy.2023.0135
Abstract
Background: Evidence is needed on the risks and benefits of combination therapy with Levothyroxine (LT4) + Liothyronine (LT3) for treatment of hypothyroidism.
Objective and methods: We performed a randomized double-blind placebo-controlled study to assess the effects of LT4 + LT3 therapy vs LT4 + placebo in a homogenous group of athyreotic patients, without cardiovascular risk factors during long-term replacement monotherapy with LT4. The primary objective of the study was to assess the effects of combination LT4 + LT3 therapy on heart rate, cardiac rhythm and sensitive cardiovascular parameters of cardiac morphology and function by means of electrocardiography and Doppler echocardiography. The secondary objective of the study was to evaluate patient compliance, tolerability, and potential adverse events.
Results: Thirty-eight patients with post-surgical hypothyroidism satisfying the inclusion criteria were selected form a group of three hundred patients with low-risk thyroid cancer followed for a routine follow-up; they were randomized to receive LT4 + LT3 or LT4 + placebo. Twenty-four patients were evaluated after one year of treatment. All clinical and laboratory parameters were compared to the results obtained in fifty healthy euthyroid volunteers without comorbidities, matched for gender, age, physical activity and lifestyle. Participants and clinicians remained blinded to the treatment allocation. After one year of combination therapy, a significant improvement in the diastolic function, evidenced by a significant reduction in the E/e' ratio (p =0.046) and its positive trend over time, was observed in the LT4 + LT3 group vs. the LT4 + placebo group. In addition, the univariate analyses showed a significant relationship between F-T3 levels (pg/ml) with Δ of variation of E/e' ratio in LT4 + LT3 group. (Standardized ß coefficient = 0.603 (CI 95%: 0.001 - 1.248), p-value = 0.050) after combination therapy. No adverse events including tachycardia, arrhythmias, atrial fibrillation, or other important events occurred between the first administration and the end of the study.
Conclusion: In this preliminary report, combination treatment with LT4 + LT3 induced favorable changes in cardiovascular parameters of diastolic function without any adverse cardiovascular events.
Trial registration: EUDRACT n: 2017-001261-25
As so often, the rest of the paper is behind an insurmountable paywall: